Therapeutic Response
not BRCA2 pathogenic variants status confers therapeutic sensitivity to Niraparib in patients with Peritoneal Serous Carcinoma.
Statements
| Source and description |
|---|
not BRCA2 pathogenic variants status confers therapeutic sensitivity to Niraparib in patients with Peritoneal Serous Carcinoma.
| Source and description |
|---|